Primary myelofibrosis is characterized by the development of fibrosis in the bone marrow that contributes to ineffective hematopoiesis. Bone marrow fibrosis is the result of a complex and not yet fully understood interaction among megakaryocytes, myeloid cells, fibroblasts, and endothelial cells. Here, we report that >30% of the endothelial cells in the small vessels of the bone marrow and spleen of patients with primary myelofibrosis have a mesenchymal phenotype, which is suggestive of the process known as endothelial-to-mesenchymal transition (EndMT). EndMT can be reproduced in vitro by incubation of cultured endothelial progenitor cells or spleen-derived endothelial cells with inflammatory cytokines. Megakaryocytes appear to be implicated in this process, because EndMT mainly occurs in the microvessels close to these cells, and because megakaryocyte-derived supernatant fluid can reproduce the EndMT switch in vitro. Furthermore, EndMT is an early event in a JAK2-V617F knock-in mouse model of primary myelofibrosis. Overall, these data show for the first time that microvascular endothelial cells in the bone marrow and spleen of patients with primary myelofibrosis show functional and morphologic changes that are associated to the mesenchymal phenotype. Primary myelofibrosis (PMF) is one of the family of myeloproliferative neoplasms, which is a heterogeneous group of related diseases that also includes polycythemia vera and essential thrombocythemia. 1 Myeloproliferative neoplasms are clonal malignant disorders that are characterized by oncogenic transformation of the hematopoietic progenitor cell compartment, which causes abnormal proliferation of the myeloid lineages driven by a hypersensitivity to regulatory growth factors. 2 Fifty percent to 60% of patients with myeloproliferative neoplasms harbor a somatic gain-of-function mutation in the Janus kinase 2 (JAK2) gene, which results in the translation of the mutated JAK2-V617F protein. Because this mutation is in the pseudo-kinase JH2 domain, the autoinhibitory function of JAK2-V617F is impaired. This results in constitutive activation of the downstream JAK2 signaling pathways, PMF clonal myeloproliferation primarily induces bone marrow fibrosis and osteosclerosis, with extramedullary hematopoiesis in the spleen, which results in splenomegaly and abnormal cytokine overexpression. 6, 7 Debilitating symptoms include anemia, thrombosis, and general malaise. Ineffective erythropoiesis and extramedullary hematopoiesis can be the cause of anemia and splenomegaly. No definitive therapy is currently available for patients with PMF. The only potentially curative treatment is allogeneic stem cell transplantation, although this is associated with high rates of mortality and morbidity. 8 Despite being a hematopoietic disease, among the myeloproliferative neoplasms, involvement of the endothelial lineage has been reported only for PMF, 9e11 although this has been poorly characterized to date. In the bloodstream of patients with PMF, the numbers of endothelial progenitor cells (EPCs) are significantly higher than in healthy donors and for other myeloproliferative neoplasms. 9 Moreover, a massive neoangiogenesis is observed in bone marrow 12, 13 and spleen 14 of patients with PMF, which shows a high concentration of the proangiogenic factors vascular endothelial growth factor 15 and fibroblast growth factor-2. 16 Although fibroblasts are believed to be directly implicated in fibrosis in PMF bone marrow, other cells might also contribute to this phenomenon, such as endothelial cells. Under inflammatory conditions, endothelial cells can undergo a biological process known as endothelial-to-mesenchymal transition (EndMT), such as during arteriosclerosis 17 or in the tumor stroma. 18 This phenotypic switch is characterized by coexpression of endothelial and mesenchymal markers and by changes to some of the phenotypic characteristics, such as acquisition of an elongated fibroblastoid morphologic structure and increased migratory properties. 18, 19 Physiologically, EndMT takes place during the formation of the heart cushion in the embryo, 20e22 but it can be reactivated in adults under pathologic conditions. 23e25 The EndMT program can be induced by transforming growth factor (TGF)-b and the bone morphogenetic proteins (BMPs), and it can significantly contribute to fibrotic progression in different diseases. 23,26e28 In the present study, we show that endothelial cells from the microvasculature of bone marrow and spleen can undergo the EndMT switch during the development of PMF in both patients and a mouse model of PMF. This process occurs during the early stages of fibrotic degeneration and can be mediated by the release and activation of TGF-b and other inflammatory cytokines by megakaryocytes and platelets. Thus, EndMT can contribute to the development and maintenance of bone marrow fibrosis and spleen dysplasia in PMF.
Materials and Methods

Tissue Samples from PMF Patients
Bone marrow, spleen tissue, and EPCs from peripheral blood of patients with PMF were collected at the Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico San Matteo (Pavia, Italy). The diagnosis of PMF was established according to the World Health Organization 2008 criteria 29 and the Italian Consensus Conference criteria. 30 The clinical features of patients with PMF are summarized in Supplemental Table S1 . The healthy control subjects were staff members or donors for scientific research. All of the patients and donors approved and signed the informed consent. Bone marrow sections from healthy donors were purchased from Labospace (Milano, Italy).
Mice
The C57Bl/6J mice (8 to 12 weeks of age) for isolation of endothelial cells from the spleen (SECs) and of megakaryocytes and for purification of platelets were purchased from Charles Rivers Laboratories (Calco, Italy).
The conditional JAK2 FLEX/WT KI mice have been described previously, 31 and they were crossed with transgenic mice that expressed Cre-recombinase under the Vav promoter, to obtain mice expressing the JAK2-V617F mutation in heterozygosity, namely JAK2 V617F/WT KI.
32
The animal experimentation was approved by the FIRC Institute of Molecular Oncology Institutional Animal Care and Use Committee and was performed according to the guidelines for the regulation of animal experimentation of the Italian Ministry of Health.
Cells
Murine SECs were isolated and immortalized as described previously. 33 Briefly, the mouse spleens were collected under sterile conditions and dissociated with 1.5 mg/mL collagenase type I (Roche, Mannehim, Germany) and DNase 25 mg/mL (Roche) for 3 hours at 37
C. The resulting cell suspension was filtered through a nylon screen (70-mm mesh), centrifuged, and plated. Two days later, the heterogeneous population of SECs was infected with polyoma middle T antigen to specifically immortalize them. 34 The SECs were cultured in 0.1% gelatin-coated flasks in MCDB131 medium (Life Technologies, Paisley, UK), supplemented with 20% North American fetal bovine serum (HyClone, South Logan, UT), 50 mg/mL endothelial cell growth supplement (made from calf brain), 100 mg/mL heparin (Sigma-Aldrich, St. Louis, MO), 100 U/L penicillin/ streptomycin (Sigma-Aldrich), and 2 mmol/L L-glutamine (Sigma-Aldrich). The cell-starving medium consisted of MCDB131 medium with 1% bovine serum albumin (BSA; EuroClone, Milano, Italy).
EPCs from healthy donors and patients with PMF were isolated according to protocols reported previously 35 and were grown on collagen-Iecoated plates in Endothelial Cell Growth Medium-2 supplied with Endothelial Cell Growth Medium-2 MV SingleQuots kits (Lonza, Cologne, GmbH, Germany). 
Cell Treatments
To induce the EndMT phenotype, the SECs and EPCs were stimulated with a cocktail of proinflammatory cytokines that included TGF-b, IL-1b, and tumor necrosis factor (TNF)-a (Peprotech, Rocky Hill, NJ), as described previously, 36 or with BMP6 (R&D Systems, Minneapolis, MN). The SECs were also treated with the TGF-b inhibitors LY-2109761 (SelleckBio, Munich, Germany) and dorsomorphin homolog 1 (DMH1; Tocris Bioscience, Bristol, UK).
Megakaryocyte Differentiation from Murine Fetal Liver
Murine fetal liver cells were collected at embryonic days 13 to 15, mechanically dissociated, and cultured for 3 days in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with 10% fetal calf serum (Life Technologies), 100 U/L penicillin/streptomycin, 2 mmol/L L-glutamine, and 10 ng/mL recombinant mouse thrombopoietin (PeproTech). The cells were then layered on a single-step gradient (1.5% to 3.0% BSA), and the megakaryocytes were allowed to settle for 30 minutes at room temperature. The megakaryocyte pellet was washed and resuspended in complete medium, to a final concentration of 0.2 Â 10 9 cells/mL. 37 
Platelet Purification and in Vitro Induction of Platelet and Megakaryocyte Release Reactions
Platelet purification from peripheral blood of mice was performed as described previously. 38 Briefly, the blood was collected from the inferior vena cava and pooled in buffered 3.2% citrate-dextrose solution, pH 5.2, and diluted with two parts of Ca 2þ -free and Mg 2þ -free Tyrode buffer, pH 6.5, followed by centrifugation at 300 Â g for 7 minutes, to obtain the platelet-rich plasma. This plateletrich plasma was further diluted in two parts of Tyrode buffer, pH 6.5, supplemented with 0.6 U/mL apyrase a (New England BioLabs, Ipswich, MA) and centrifuged at 600 Â g for 15 minutes, to obtain the platelet pellet. The platelets were then resuspended in Tyrode buffer, pH 7.4, that contained 2 mmol/L CaCl 2 , to a final concentration of 0.2 Â 10 9 platelets/mL. The platelets and megakaryocytes were incubated with 2 U/mL recombinant thrombin (Sigma-Aldrich) for 15 minutes at room temperature. Then 2 U/mL recombinant hirudin (Sigma-Aldrich) was added for 15 minutes to inactivate the thrombin. An additional centrifugation at 600 Â g for 15 minutes led to the separation of the supernatant fluid from the pellet. The pellet was then resuspended in Tyrode buffer, pH 7.4, and both the supernatant fluid and the pellet were supplemented with 0.5% BSA and 70 mmol/L HCl. After 30 minutes, 70 mmol/L NaOH was added to neutralize the acid pH environment of the solutions.
For the TGF-b blocking experiments, the megakaryocyte supernatant fluids were preincubated with an antieTGF-b neutralizing antibody (clone 1D11; R&D Systems) or the corresponding isotype control antibodies (R&D Systems).
IF Analysis
For immunofluorescence (IF), confluent cell monolayers were fixed with 4% formaldehyde that was freshly prepared from paraformaldehyde in phosphate-buffered saline (PBS). After 15 minutes at room temperature, the fixed cells were permeabilized with 0.5% Triton X-100 for 5 minutes. The antibodies for the blocking (1 hour), primary (2 hours), and secondary (1 hour) incubations were diluted in PBS with 2% BSA. The appropriate fluorophore-conjugated secondary antibodies were used (Alexa-488, Alexa-555, Alexa-647, respectively; Molecular Probes, Eugene, OR). The nuclei were visualized using DAPI.
Tissue Samples
Frozen bone marrow and spleen biopsies were sectioned (thickness, 5 mm) using a cryotome (Leica, Wetzlar, Germany), and the sections were mounted on Superfrost glass slides (Thermo Scientific, Waltham, MA) and dried. The sections were then fixed for 15 minutes with 4% formaldehyde that was freshly prepared from paraformaldehyde in PBS at room temperature, washed with PBS, permeabilized with 0.1% TritonX-100ePBS, and blocked with PBS containing 5% donkey serum and 2% BSA for 3 hours at room temperature.
Murine paraffin-embedded bone marrow and spleen were sectioned (thickness, 5 mm) using a microtome (Leica) and deparaffinized through descending concentrations of ethanol. Antigen unmasking was performed in 0.25 mmol/L EDTA, pH 8.0, for 50 minutes at 95 C. The sections were then blocked with Tris-buffered saline (TBS) containing 5% donkey serum, 0.05% Triton X-100, and 2% BSA, for 1 hour at room temperature. Incubations with primary antibodies on both the cryosections and paraffin sections were performed in blocking solution overnight at 4 C. Tissue sections were then washed and incubated with the appropriate fluorophore-conjugated secondary antibodies (Molecular Probes) for 1 hour at room temperature. The nuclei were visualized with DAPI. The specimens were mounted with Vectashield (Vector Laboratories, Burlingame, CA).
Confocal microscopy was performed using a confocal microscope (TCS SP2; Leica). Image acquisition was performed using a 63Â/1.4 NA oil-immersion objective (HCX PL APO 63Â Lbd Bl; Leica), and with spectral detection bands and scanning modalities optimized for the removal of channel cross talk. The Leica confocal software version 2.61 and ImageJ software version 1.49 (NIH, Bethesda, MD) were used for the data analysis. Only adjustments of brightness and contrast were used in the preparation of the figures, using Photoshop software version 13.0.6 (Adobe, San Jose, CA). Hematoxylin and eosin staining of the paraffin-embedded sections was performed according to standard protocols.
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IP Analysis
For immunoprecipitation (IP) cells were solubilized in JS buffer (20 mmol/L HEPES, pH 7.5, 1.5 mmol/L MgCl 2 , 5 mmol/L EGTA, 150 mmol/L NaCl, 1% Triton X-100, 0.5% glycerol), protease inhibitors (Roche), and phosphatase inhibitors (Sigma-Aldrich) on ice for 20 minutes. Precleared cell extracts were subjected to antibody precipitation at 4 C, and immunocomplexes were captured using protein G-Sepharose beads (GE Healthcare Europe GmbH, Milano, Italy). Immunoprecipitated material was separated using Tris-glycine sodium dodecyl sulfate-PAGE, blotted onto nitrocellulose membranes, and analyzed by standard methods.
Immunoblot Analysis
Total protein was extracted by solubilizing the cells in boiling Laemmli buffer. Lysates were incubated for 10 minutes at Boxed areas are shown at higher magnification to the right. Data are expressed as means AE SD. n Z 3 healthy CTRL donors (AeC); n Z 8 patients with PMF (AeC). *P < 0.05, **P < 0.01. Scale bars: 30 mm (AeC, main images); 10 mm (AeC, higher magnification). CTRL, control; JAK2, Janus kinase 2; p-, phospho; wt, wild-type. C and then centrifuged at 10,000 Â g for 5 minutes to remove the cell debris. The supernatant fluids were collected, and their protein concentrations were determined using BCA Protein Assay kits (Pierce-ThermoFisher, Rockford, IL), according to the manufacturer's instructions. Equal amounts of protein were loaded onto the acrylamide gels at different concentrations and were separated using sodium dodecyl sulfate-PAGE, transferred to Protran nitrocellulose hybridization transfer membranes (pore size, 0.2 mm; ThermoFisher, Rockford, IL), and blocked for 1 hour at room temperature in TBS with Tween-20 (TBST) and 5% BSA. The membranes were then incubated overnight at 4 C, with the primary antibodies diluted in TBST containing 5% BSA. The membranes were rinsed at least three times with TBST and then incubated with horseradish peroxidase-linked secondary antibodies (Cell Signaling Technology, Danvers, MA) for 1 hour at room temperature. After three washes, the membranes were incubated with Amersham ECL Western blot (WB) detection reagents (Amersham Biosciences, Uppsala, Sweden) for 1 minute and exposed using a ChemiDoc XRS gel imaging system (Bio-Rad, Hercules, CA), for the required time.
RT-PCR
For the gene expression analysis, total RNA was isolated using RNaesy Micro kits (Qiagen, Valencia, CA), and 500 ng of total RNA was reverse transcribed with random hexamers (High-Capacity cDNA Archive kits; Applied Biosystems, Foster City, CA) according to the Figure 2 Endothelial progenitor cells (EPCs) undergo endothelial-to-mesenchymal transition (EndMT) under proinflammatory conditions. EPCs (assessed as endothelial colony-forming cells) from healthy donors and patients with PMF were treated with a cocktail of proinflammatory cytokines: 5 ng/mL transforming growth factor (TGF)-b1, 100 U/mL IL-1b, and 100 U/mL tumor necrosis factor (TNF)-a for 72 hours. A: Representative images of expression of endothelial specific markers vascular endothelial (VE)-cadherin (red) and claudin5 (green) in EPCs before and after treatment. DAPI staining (blue) shows nuclei. B: Quantification of quantitative real-time RT-PCR analysis of EPCs for expression of mesenchymal markers Snail, CD44, N-cadherin, and fibronectin (FN). mRNA is expressed as 2
ÀDCt
, as normalized to GAPDH. C: Representative images of phase contrast microscopy for morphologic structure of EPCs before (untreated) and after cytokine treatment. Data are expressed as means AE SD. n Z 3 healthy CTRL donors (A); n Z 6 patients with PMF (A); n Z 3 for each analysis (B). **P < 0.01. Scale bars: 10 mm (A); 30 mm (C). CTRL, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; JAK2, Janus kinase 2; PMF, primary myelofibrosis; wt, wild-type.
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The American Journal of Pathology -ajp.amjpathol.orgajp.amjpathol.org -The American Journal of Pathology manufacturer's instructions. The cDNAs were amplified using the TaqMan gene expression assay (Applied Biosystems) in a thermocycler (7900 HT; ABI/Prism, Applied Biosystems).
Antibodies
The following antibodies were used for IF, WB, and IP anal- 
Statistical Analysis
Statistical significance was evaluated using two-tailed nonpaired t-tests with the significance level at P < 0.05.
Results
Microvascular Endothelial Cells of Bone Marrow and Spleen of Patients with PMF Express Mesenchymal Markers
Analysis of the bone marrow sections of patients with PMF for expression of different markers demonstrated that a subpopulation of endothelial cells were costained with the specific marker VE-cadherin and Fsp1 ( Figure 1A) . The vessels were also surrounded by high levels of fibronectin, which is usually low or absent in the bone marrow vasculature of healthy individuals. The spleen of the patients with PMF were then analyzed, where extramedullary hematopoiesis primarily takes place and the bone marrow hematopoietic niche can be recreated. Spleen sections showed that Fsp1 was coexpressed with VE-cadherin in the endothelial cells of PMF specimens but not in control spleens ( Figure 1B) . Furthermore, these vessels showed strong staining for fibronectin and collagen I ( Figure 1B) . Fsp1, fibronectin, and collagen I are not present in the normal vessels of the spleen, but they can be up-regulated when endothelial cells undergo EndMT.
Under other pathologic conditions, TGF-b is the main EndMT inducer. 18,39e41 The spleen sections from the patients with PMF showed strong staining with the antieTGFb antibody (Supplemental Figure S1) , and the number of endothelial cells that were positive for the TGF-b downstream signaling molecule phospho-Smad2/3 was increased for the patients with PMF compared with controls ( Figure 1,  C and D) . The presence of the JAK2-V617F mutation in the hematopoietic lineage did not significantly change the appearance of EndMT, TGF-b production or Smad phosphorylation for the patients with PMF.
EPCs and SECs Develop EndMT in an Inflammatory Environment
To investigate the molecular mechanisms through which endothelial cells undergo EndMT in the patients with PMF, circulating EPCs were isolated and cultured as endothelial colony-forming cells 35 ; these cells have been reported to be . SECs were treated with 5 ng/mL recombinant TGF-b1, 100 U/mL IL-1b, and 100 U/mL tumor necrosis factor (TNF)-a for 120 hours under starving condition. A: Representative images of phase contrast microscopy for morphologic structure of SECs before (untreated) and after cytokine treatment. B: Quantification of VE-cadherin and N-cadherin expression at transcriptional and protein levels, by RT-PCR and as representative images of Western blot analysis (right), respectively. C: Quantification of mRNA levels of claudin5, a-SMA, fibronectin (FN), fibroblast-specific protein 1 (Fsp1), collagen I, serpin1, Snail, Bmp6, and CD44. Western blot analysis (right) of CD44 and FN expression in SECs treated with proinflammatory cytokines. D: Quantification of mRNA levels after 100 ng/mL BMP-6 treatment for 96 hours, for claudin5, a-SMA, FN, Fsp1, collagen I, serpin1, and Snail, by RT-PCR. For all RT-PCR analyses, mRNA is expressed as 2
ÀDCt , as normalized to 18 seconds. E: Representative Western blot analysis for expression of total levels of Smad1 and Smad3 and their phosphorylated forms (pSer463/465, pSer423/425, respectively) in SEC lysates after stimulation with 5 ng/mL TGF-b1, 100 U/mL IL-1b, and100 U/mL TNF-a, or with 100 ng/mL BMP-6, for 45 minutes. All Western blot analyses were representative of independent experiments with tubulin or vinculin used to monitor sample loading. Data are expressed as means AE SD. n Z 3 independent experiments for Western blot analysis. *P < 0.05, **P < 0.01. Scale bar Z 30 mm. a-SMA, a-smooth muscle actin; EndMT, endothelial-to-mesenchymal transition; VE, vascular endothelial cadherin.
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À , and CD14 À . 35, 42 EPCs circulate in high numbers in patients with PMF 9 and can reach the spleen through the circulation. To reproduce the proinflammatory environment of the PMF disease, the EPCs were cultured and stimulated with a cocktail of cytokines, which included TGF-b, IL-1b, and TNF-a. 36 In a previous study, 28 we identified several markers of EndMT that were very low or absent in the resting endothelium. Cytokine-stimulated EPCs from both healthy donors and the patients with PMF showed decreases in the endothelial markers claudin-5 and VE-cadherin at cell-to-cell contacts (Figure 2A) , with up-regulation of the mesenchymal markers Snail, N-cadherin, fibronectin, and CD44 ( Figure 2B) . Moreover, the switch toward a mesenchymal phenotype induced cultured EPCs to acquire an elongated, fibroblast-like spindle shape ( Figure 2C ). No significant differences were found for the expression of the mesenchymal markers in the control EPCs or those from the patients with PMF, whether they had the JAK2-V617F mutation in the hematopoietic lineage ( Figure 2B ).
The spleen microenvironment of the patients with PMF has higher levels of TGF-b 43 and increased microvessel density.
14 A recent study showed that SECs of patients with PMF can express the JAK2-V617F mutation. 11 This prompted us to also analyze the endothelial cells of splenic origin (ie, SECs), taking advantage of a murine SEC line.
Endothelial cells from the mouse spleen microvasculature were isolated, immortalized, and analyzed in terms of their morphologic structure and junctional marker expression. These murine SECs had the typical cobblestone structure and the expected expression and distribution of endothelial markers (ie, VE-cadherin, JAM-A, platelet endothelial cell adhesion molecule) (Figure 3 and Supplemental Figure S2 ). When these SECs were stimulated with TGF-b, IL-1b, or TNF-a, they acquired a spindle-shaped morphologic characteristic ( Figure 3A ) and showed partial down-regulation of VE-cadherin and upregulation of N-cadherin, at both the transcriptional and protein levels ( Figure 3B ).
In the IF analysis, in endothelial cells activated by the cocktail of cytokines, N-cadherin was up-regulated and distributed at cell-to-cell contacts, but this was irregular and was not the case for all of the cells (Supplemental Figure S2) . At this point, VE-cadherin was still expressed and present at the intercellular junctions. a-Catenin, b-catenin, g-catenin/plakoglobin, and p120 were also seen at the intercellular junctions. In the IP analysis followed by WB analysis (Supplemental Figure S3) , N-cadherin was seen to associate with a-catenin, b-catenin, g-catenin/ plakoglobin, and p120, although the relative levels of the intracellular partners linked to N-cadherin was lower than to VE-cadherin.
Other junctional adhesion proteins, such as JAM-A and platelet endothelial cell adhesion molecule, were organized as expected at the intercellular junctions, in both the control and cytokine-treated cells undergoing EndMT (Supplemental Figure S2) .
The acquisition of the EndMT phenotype was further supported by down-regulation of endothelial markers, such as claudin5, and up-regulation of a-smooth muscle actin (a-SMA), fibronectin, Fsp1, collagen I, serpine1, Snail, BMP6, and CD44 ( Figure 3C ). The induction of CD44 and fibronectin was further validated by WB analysis ( Figure 3C ). Interestingly, among the genes that were up-regulated by the inflammatory cytokines, there was a significant increase in the BMP6 transcript ( Figure 3C) . The BMPs are a group of heterogeneous ligands that belong to the TGF-b superfamily, and their aberrant expression is seen for vascular disorders.
28 BMP6 addition to SECs triggered the phosphorylation of Smad1 and Smad 3 ( Figure 3E ) and down-regulated the expression of endothelial-specific molecules, such as claudin5, with concurrent up-regulation of the EndMT mesenchymal markers a-SMA, fibronectin, Fsp11, collagen I, serpine1, and Snail ( Figure 3D) .
Overall, these data show that both human endothelial colony-forming cells of patients with PMF and murine SECs can undergo mesenchymal transition on activation with inflammatory cytokines. This effect is sustained through up-regulation of BMP6.
Megakaryocytes and Platelets Can Induce EndMT
To investigate the source of the inflammatory cytokines that can induce EndMT in vivo, the localization of megakaryocytes in the spleen of healthy donors and patients with PMF was determined. PMF megakaryocytes are characterized by dysplastic hyperplasia and by high levels of TGF-b. 41, 44, 45 Only splenic tissue from the patients with PMF, and not from the healthy donors, showed cells that were positive for the megakaryocyte marker CD41a (Figure 4, A and B) .
In the spleen sections from patients with PMF, endothelial cells that were double-positive for VE-cadherin and the mesenchymal marker Fsp1 were in close proximity to megakaryocytes ( Figure 4C ). In contrast, in the healthy donors, megakaryocytes were low or absent, and the vessels did not stain for Fsp1 ( Figure 4C ). These data suggest that megakaryocytes in spleens from patients with PMF can induce EndMT, as a close and potent source of TGF-b and other cytokines.
To determine whether inflammatory cytokines that are released from a-granules of both megakaryocytes and platelets, and in particular TGF-b, can indeed trigger EndMT, murine megakaryocytes and platelets were isolated from fetal liver and peripheral blood, respectively. An in vitro release reaction was then induced in the megakaryocytes (Figure 4 , D and E) and in the platelet suspensions (Figure 4 , F and G) to release the content of their granules, as described previously. 46 The resulting supernatant fluids and pellets were incubated with the SECs and were seen to activate the TGF-b signaling pathway, with induction of phosphorylation of both Smad1 and Smad3 (Figure 4, D and F) and ajp.amjpathol.org -The American Journal of Pathology up-regulation of EndMT markers, such as a-SMA, BMP6, fibronectin, and serpine1 (Figure 4 , E and G). To further understand the relevance of TGF-b in this system, SECs were incubated with the megakaryocyte supernatant fluid in the presence of an antieTGF-b blocking antibody, which strongly inhibited phosphorylation of the Smads and expression of the typical EndMT markers (Supplemental Figure S4 ).
Two available inhibitors were then tested: LY-2109761, as a paneTGF-b inhibitor of TbRI and TbRII kinases, 47 and DMH1, which acts on BMP signaling. 28 On incubation of SECs with platelet-derived supernatant fluid and pellet, and in contrast to LY-2109761, DMH1 had little effect on phosphorylation of Smad1 and Smad3 ( Figure 5A ), but it significantly down-regulated the EndMT markers ( Figure 5B) . A possible explanation for this discrepancy is that during EndMT, the endothelial cells can up-regulate BMP6 ( Figure 4D ), which in turn will contribute to the up-regulation of the EndMT markers ( Figure 3D ). DMH1 therefore might be more active on the slowly progressing up-regulation of the EndMT markers that is induced by BMP6 than on the early activation of the Smads.
It is therefore likely that megakaryocyte-derived and platelet-derived TGF-b in combination with endogenous endothelial BMP6 induces the EndMT switch observed in the bone marrow and spleen of patients with PMF.
EndMT Is an Early Event in the Development of Fibrosis in a Mouse Model of Myeloproliferative Disease
The JAK2 V617F/WT KI murine model of disease 31 was also studied, where the V617F mutation is expressed under heterozygosity in the hematopoietic compartment specifically, and where a myeloproliferative-like phenotype develops. To determine whether EndMT is an early event in fibrosis development, bone marrow and spleen sections 
ÀDCt
, as normalized to 18 seconds. Data are expressed as means AE SD. n Z 2 healthy CTRL donors (A and C); n Z 6 patients with PMF (A and C); n Z 3 independent experiments for Western blot analysis (E and G). *P < 0.05, **P < 0.01. Scale bars: 50 mm (A); 30 mm (C). a-SMA, a-smooth muscle actin; Bmp6, bone morphogenetic protein 6; CTRL, control; Fsp1, fibroblast-specific protein 1; JAK2, Janus kinase 2; p-, phospho-; SEC, spleen endothelial cell;VE, vascular endothelial cadherin; wt, wild-type.
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Hematoxylin and eosin staining revealed increased numbers of megakaryocytes in bone marrow sections of the mutated mice ( Figure 6A ), which resembled the PMF pathologic process. Both the size and weight of the spleen of the mutated mice were increased, and there was clear loss of the architecture of the organ, with no further distinction between the red and white pulp ( Figure 6A) . Conversely, the morphologic characteristics of the liver and lungs were comparable between these mutated and wild-type mice. Overall, this murine model reproduces the human myeloproliferative neoplasm disease relatively accurately. IF analysis of the JAK2 V617F/WT KI mutant showed that the bone marrowederived and spleen-derived endothelial cells coexpressed VE-cadherin and the mesenchymal markers Fsp1 and CD44 ( Figure 6B ), which was not the case for the JAK2 FLEX/WT KI (wild-type) mice. This confirmed the observations reported above for the spleen sections of the patients with PMF ( Figure 1B) .
Of note, up-regulation of Fsp1 and CD44 was already seen at the very early stages of disease development and before the detection of obvious organ fibrosis. This suggests that EndMT transition might be an early event in, and a possible trigger of, fibrosis.
Overall, the data reported here show for the first time that there is a functional change in the microvascular endothelial cells toward a mesenchymal phenotype in the bone marrow and spleen of patients with PMF. The acquisition of these mesenchymal characteristics by endothelial cells is an early event that appears to be induced by the inflammatory microenvironment where the vessels are located. The EndMT switch of the endothelial cells might contribute to the overall development of the fibrosis.
Discussion
PMF is a myeloproliferative disease that is characterized by abnormal proliferation of the myeloid lineages and excessive production of proinflammatory cytokines, which lead to the replacement of the hematopoietic environment with a fibrotic stroma. The fibrotic stroma is an important clinical problem, and intervention to limit fibrosis has so far been only palliative. Patients with PMF also experience neoangiogenesis in their bone marrow and spleen tissues and show significant increases in circulating EPCs, which suggests that an alteration in endothelial cell homeostasis might contribute to the pathologic phenotype.
In the present study, we have introduced a novel pathogenetic mechanism that can act at the onset and during progression of bone marrow fibrosis in PMF. We have shown that endothelial cells of the microcirculation of the bone marrow and spleen of patients with PMF can undergo EndMT, thus acquiring fibroblastoid characteristics. This process of EndMT is important in embryogenesis 20e22 ; however, in the adult it is associated to fibrotic degeneration in different organs, including the heart, lungs, and kidney. In both physiological and pathologic situations, EndMT is mediated by inflammatory cytokines, and in particular by TGF-b and the BMPs. 40 It was recently reported that in PMF megakaryocytes constitutively produce and release high levels of bioactive TGF-b. 41, 45 We confirmed these , as normalized to 18 seconds. Data are expressed as means AE SD. n Z 4 independent experiments. *P < 0.05, **P < 0.01. a-SMA, a-smooth muscle actin; DMH1, dorsomorphin homolog 1; DMSO, dimethyl sulfoxide; EndMT, endothelial-to-mesenchymal transition; p-, phospho-; SEC, spleen endothelial cell. ajp.amjpathol.org -The American Journal of Pathology observations in the spleen of these patients with PMF, where TGF-b localized in the stroma and Smad activation in the endothelial cells. We have also shown that the EndMT switch of endothelial cells is localized in regions where the vessels are contiguous to megakaryocytes. A direct incubation of SECs with megakaryocytes or platelet supernatant fluid and pellet induced EndMT, which was abrogated by TGF-b inhibitors. Other factors in the bone marrow stroma that can be released by megakaryocytes (such as IL-1a) can also contribute to EndMT and act synergistically with TGF-b.
Endogenous BMP6 is elevated in SECs undergoing EndMT, and in a previous study we demonstrated that this cytokine can significantly contribute to the EndMT switch. 28 The involvement of the BMP subfamily in the development of PMF is not new; high levels of BMP1, BMP6, and BMP7 and BMP-receptor 2 mRNAs have been reported for bone marrow biopsies from patients with PMF in the advanced stages of the disease, 48 and BMPs have been suggested to have roles in sustaining the progression of fibrosis. These observations suggest that inhibitors of the Smad pathway that act downstream TGF-b or BMP6 might be effective in inhibiting or reverting EndMT and possibly in reducing fibrosis in vivo.
These data showed no significant differences in expression of the EndMT markers in the vessels of patients carrying the JAK2-V617F mutation in the hematopoietic lineage. Infection of endothelial cells in vitro with a vector expressing the JAK2 mutant also did not change their EndMT or their sensitivity to inflammatory stimuli (data not 
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EndMT is a relatively common reaction of different types of endothelial cells when in contact with an inflammatory microenvironment, as shown here and elsewhere. 28, 36 Although it is well known that megakaryocytes are produced and differentiate in the bone marrow to originate platelets, 49 we observed that they are present also in the spleen of patients with PMF and that they can contribute to EndMT also in this organ. Splenic fibrosis is not usually observed for patients with PMF. In the study of the mouse model of myeloproliferation here, we saw that they developed splenic fibrosis quite early in the kinetics of evolution of the disease. This effect paralleled the expression of the EndMT markers also at very early stages of fibrotic degeneration. The apparent difference between the mouse model and patients with PMF might be due to the different histologic features of the splenomegaly. In mice, the evolution of the disease is particularly rapid, and splenomegaly is coupled to marked splenic fibrosis that can be seen from the early stages of the disease. In patients with PMF, the excessive splenomegaly is due to extramedullary hematopoiesis, 6, 50 and it develops before there are signs of fibrosis, which might, however, have a later evolution. Indeed, we have also seen signs of EndMT in the spleen of some patients with prefibrotic PMF (eg, patients 3 and 5) (Supplemental Table S1 and Figure 1B) , which further underlines the early appearance of this phenomenon in the progression of the disease.
In addition, the JAK2 mutation is not present in all of the patients with PMF, and other relevant mutations have been detected in association with this disease. 5 The animal model therefore reproduces only in part the most common features of PMF.
Although the role of EndMT might be to contribute to fibrosis, an alternative possibility is that the subset of endothelial cells that expresses the mesenchymal markers also contributes to the onset of the disease. The close association of endothelial cells with megakaryocytes suggests that there might be cross talk between these two cell types. Endothelial cells that are undergoing EndMT might produce growth and differentiating factors that might contribute, in turn, to the altered functional behavior of megakaryocytes. The gene for fibronectin was among those that were strongly up-regulated by the megakaryocyte and platelet release reactions. Fibronectin regulates megakaryocyte interactions with the bone marrow niche to modulate expansion, maturation, and pro-platelet formation. 51, 52 Moreover, a recent study demonstrated that when bone marrow hematopoietic stem cells are cultured in an in vitro system in the presence of different extracellular matrix components, only fibronectin can increase cell survival and proliferation of the bone marrow precursors, and in the presence of thrombopoietin, fibronectin strongly increases the pool of megakaryocyte progenitors. 53 Therefore, it is tempting to speculate that in PMF the cross talk between endothelial cells and megakaryocytes gives rise to a pathologic autoefeed-forward process: the TGF-b produced by the megakaryocytes is sensed by the endothelial cells, which in response undergo EndMT and strongly up-regulate the expression of fibronectin or other growth factors. This will continuously feed the megakaryocytes expansion and maturation, thus fostering myelofibrosis. Further and deeper analysis of the endothelial cellemegakaryocyte niche is needed to define this concept in more detail. ajp.amjpathol.org -The American Journal of Pathology
